-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
•
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first quarter of 2023, showing an 8% year-on-year (YOY) decrease in revenues in constant currency terms to GBP 6.95 billion (USD 8.67 billion). The decline is attributed to reduced demand for COVID-19 treatments, most notably the…
-
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
•
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III clinical study for the CD22 monoclonal antibody (mAb) SM03, also known as suciraslimab, has successfully reached the primary endpoint in patients with rheumatoid arthritis (RA). Study Design and Efficacy of SuciraslimabThe randomized, double-blind, multi-center, placebo-controlled…
-
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center, randomized, open, positive-controlled Phase III RENOTORCH study has reached pre-set endpoints at the interim analysis stage. The study evaluates the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with axitinib for the treatment of moderate to…
-
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical study for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has successfully reached the primary endpoint in patients with HR+/HER2- advanced breast cancer that has progressed after previous endocrine therapy combined with fulvestrant. Positive Mid-Term Analysis…
-
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a…
-
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market filing for the Category 1 drug prusogliptin, intended for the treatment of type 2 diabetes, has been accepted for review by the National Medical Products Administration (NMPA). Clinical Study Results and Efficacy of PrusogliptinA clinical…
-
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1 receptor-targeted drug, Zerviate (OT-1001), has been granted priority review status by the National Medical Products Administration (NMPA). Zerviate’s Origins and Market PresenceZerviate, originally developed by France-based pharmaceutical firm Nicox SA, is an innovative formulation of…
-
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
•
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be…
-
Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma
•
Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196) has dropped plans to sell its stake in Indian pharmaceutical firm Gland Pharma Ltd (NSE: GLAND). This decision comes after Fosun was reported in November 2022 to have been considering the sale of…
-
LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product
•
Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with South Korea-headquartered LegoChem Biosciences, Inc. Under this agreement, the two companies will leverage LaNova’s antibody assets and LCB’s antibody-drug conjugate (ADC) technology platform to develop an innovative ADC product. LaNova Medicines: A Clinical-Stage R&D CompanyEstablished…
-
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced plans to enter into an exclusive licensing agreement with Shenyang 3SBio Co., Ltd. The deal grants 3SBio extensive rights, including development, regulatory, manufacturing, use, sales, export, and import, for its antitumor programs 602, 609, 705,…
-
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings for its PCSK9 monoclonal antibody (mAb) ongericimab (JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia to the National Medical Products Administration (NMPA). Phase III and II Clinical Studies Support FilingsOngericimab is currently in…
-
Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor, has entered into a partnership with Japanese firm Chugai Pharmaceutical to jointly establish an angina pectoris center. This collaboration aims to integrate medical expertise with technological innovation to enhance coronary heart disease management. Advancing Coronary…
-
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing in its Phase III registrational clinical trial (CTR20212816) for BBM-H901, a gene therapy for hemophilia B. The therapy is developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., a wholly owned subsidiary of BBM.…
-
Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai Escugen, aimed at advancing the research, development, and manufacturing of antibody-drug conjugates (ADCs). The collaboration extends from late clinical development through to the commercialization phase, with financial details undisclosed. Leveraging Tot Bio’s Expertise in ADC…
-
Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its US partner Visus Therapeutics Inc., has published positive topline results from the pivotal Phase III BRIO-I trial. BRIO-I Trial Success and Regulatory MilestonesThe BRIO-I trial successfully met the pre-specified primary study endpoints that were agreed…
-
Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
•
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts. Company Background…
-
Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch
•
US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical Technology Co. The agreement grants Liuqiang exclusive rights to develop and commercialize Sable’s microneedle patch, which includes SBL-003 and SBL-004, in Greater China. The patch is designed for targeted aesthetic fat reduction through a process…
-
Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China
•
Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment of USD 40.6 million in a new factory located in Suzhou. The facility will specialize in the manufacturing of endoscope products, reflecting the company’s commitment to the Chinese market. Growing Significance of the Chinese Market…
